Advanced Adjuvant Systems
SPI Pharma partners strategically to make affordable, stable vaccine adjuvants accessible worldwide. While past innovations were often costly, or unavailable for licensing, our mission is to deliver scalable, next-generation adjuvant systems that combine performance, stability, and commercial availability for global vaccine developers.
Powering the Next Generation of Vaccines
SPI Pharma, QVANT and Inimmune are redefining what’s possible in vaccine development with advanced adjuvant systems that spark stronger immune responses and speed innovation to market. Together, we’re uniting world-class science with global scale to bring breakthrough vaccine technologies to patients worldwide.
Our Portfolio of Adjuvants
Valens™ T4Q
Valens T4Q combines INI-2002, a fully synthetic TLR4 agonist, with QS-21 in a liposomal formulation. It elicits robust Th1-biased immune responses comparable to those achieved with approved adjuvant systems used in malaria and shingles vaccines containing MPLA and QS-21. Adjuvant patent protection extends through 2039.
T4Q is available in two configurations:
T4QGH – formulated with QS-21GH to enhance affordability
T4QXP – formulated with high-grade QS-21XP (>95% purity)
Valens™ T4AH
Valens™ T4AH combines INI-2002, a fully synthetic TLR4 agonist, with aluminum hydroxide gel. The combination drives strong cellular and antibody responses.
T4SE (Pipeline Adjuvant)
T4SE is an oil-in-water squalene emulsion combined with INI-2002, a fully synthetic TLR4 agonist. Its composition mirrors adjuvant systems approved for human influenza vaccines, with the addition of INI-2002 to enhance and extend overall adjuvant performance.
T4Q VET (Pipeline Adjuvant)
T4Q VET is a emulsion-based adjuvant that combines INI-2002, a synthetic TLR4 agonist, with QSapTM VET, a veterinary-grade saponin. Developed for animal health applications, it represents a next-generation, scalable adjuvant platform designed to support innovative veterinary vaccine formulations.